Welcome to our dedicated page for Sutro Biopharma SEC filings (Ticker: STRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sutro Biopharma, Inc. (STRO) SEC filings page on Stock Titan provides access to the company’s public filings as reported to the U.S. Securities and Exchange Commission. Sutro is a clinical-stage oncology company focused on antibody-drug conjugates (ADCs), and its filings offer detailed insight into how it reports financial results, manages risk, and discloses material events related to its ADC pipeline and corporate operations.
Investors can review current reports on Form 8-K, where Sutro has disclosed items such as quarterly financial results, organizational restructuring designed to prioritize its ADC programs and extend its cash runway, and notices from Nasdaq regarding minimum bid price compliance. Additional 8-K filings describe actions like the 1-for-10 reverse stock split of its common stock and subsequent confirmation that the company regained compliance with Nasdaq Listing Rule 5450(a)(1).
Beyond event-driven 8-Ks, users can use this page to locate annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain more extensive information on Sutro’s research and development activities, collaboration agreements, and financial condition. For those tracking management and ownership changes, insider transaction reports on Form 4 and related filings can also be accessed to see how executives and directors transact in STRO shares.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as pipeline updates, restructuring charges, collaboration revenue, and listing status developments. Real-time updates from EDGAR ensure that new Sutro Biopharma filings appear promptly, while AI-generated overviews provide a starting point for deeper review of the full SEC documents.